JPS6160837B2 - - Google Patents
Info
- Publication number
- JPS6160837B2 JPS6160837B2 JP54004411A JP441179A JPS6160837B2 JP S6160837 B2 JPS6160837 B2 JP S6160837B2 JP 54004411 A JP54004411 A JP 54004411A JP 441179 A JP441179 A JP 441179A JP S6160837 B2 JPS6160837 B2 JP S6160837B2
- Authority
- JP
- Japan
- Prior art keywords
- chromone
- formula
- bromine
- uric acid
- compound represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- -1 chromone compound Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 2
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 10
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229940116269 uric acid Drugs 0.000 description 10
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 8
- 229940075420 xanthine Drugs 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960002529 benzbromarone Drugs 0.000 description 3
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- ZORAVFNONZHSOD-UHFFFAOYSA-N 2-(3,5-dibromo-4-hydroxybenzoyl)chromen-4-one Chemical compound C1=C(Br)C(O)=C(Br)C=C1C(=O)C1=CC(=O)C2=CC=CC=C2O1 ZORAVFNONZHSOD-UHFFFAOYSA-N 0.000 description 2
- RVMGXWBCQGAWBR-UHFFFAOYSA-N 4-oxo-1-benzopyran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC(=O)C2=C1 RVMGXWBCQGAWBR-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- 229940079919 digestives enzyme preparation Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QJTAAHJJXWYZSK-UHFFFAOYSA-N [Br].CC(O)=O Chemical compound [Br].CC(O)=O QJTAAHJJXWYZSK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- CZCHIEJNWPNBDE-UHFFFAOYSA-N benziodarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(O)C(I)=C1 CZCHIEJNWPNBDE-UHFFFAOYSA-N 0.000 description 1
- 229960004411 benziodarone Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7801154A FR2414506A1 (fr) | 1978-01-17 | 1978-01-17 | Nouvelle chromone a activite medicamenteuse |
| FR7836421A FR2445326A2 (fr) | 1978-01-17 | 1978-12-27 | Nouvelle chromone a activite medicamenteuse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS54112871A JPS54112871A (en) | 1979-09-04 |
| JPS6160837B2 true JPS6160837B2 (OSRAM) | 1986-12-23 |
Family
ID=26220400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP441179A Granted JPS54112871A (en) | 1978-01-17 | 1979-01-17 | Chromone compound having drug activity |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS54112871A (OSRAM) |
| DE (1) | DE2900656C2 (OSRAM) |
| FR (1) | FR2445326A2 (OSRAM) |
| IT (1) | IT1166579B (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10256174A1 (de) * | 2002-12-02 | 2004-06-09 | Merck Patent Gmbh | 2-Benzoylchromonderivate |
-
1978
- 1978-12-27 FR FR7836421A patent/FR2445326A2/fr active Granted
-
1979
- 1979-01-10 DE DE2900656A patent/DE2900656C2/de not_active Expired
- 1979-01-16 IT IT19312/79A patent/IT1166579B/it active
- 1979-01-17 JP JP441179A patent/JPS54112871A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2445326A2 (fr) | 1980-07-25 |
| JPS54112871A (en) | 1979-09-04 |
| DE2900656C2 (de) | 1987-03-26 |
| DE2900656A1 (de) | 1979-07-19 |
| FR2445326B2 (OSRAM) | 1981-02-27 |
| IT1166579B (it) | 1987-05-05 |
| IT7919312A0 (it) | 1979-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0400011B1 (de) | Neue phenylethanolamine | |
| LU83376A1 (fr) | Nouveaux derives d'imidazo-rifamycine a activite antibacterienne | |
| US4294822A (en) | 5-Aminoalkyl-4,4,8-trialkylpsoralens | |
| DE2446010A1 (de) | 4-(monoalkylamino)benzoesaeurederivate und verfahren zu ihrer herstellung | |
| CA1282784C (fr) | Derives de la decahydroquinoleine, leur procede de preparation, les intermediaires de preparation, leur application a titre de medicaments et les compositions les renfermant | |
| DK175915B1 (da) | 5-Amino- eller substituerede amino-1,2,3-triazoler anvendelige som antiproliferative midler | |
| JPS6028836B2 (ja) | ５−メチル−イソフラボン誘導体の製造方法 | |
| DE69734246T2 (de) | Sysntheseverfahren zur herstellung von indolylquinonen und mono- und bis-indolylquinone, die durch das verfahren hergestellt sind | |
| JPS60166616A (ja) | サッカラーゼ抑制剤 | |
| JPS6026388B2 (ja) | ２−ヒドロキシメチル−３，４，５−トリヒドロキシ−ピペリジン誘導体、その製法及び利用 | |
| EP0117196B1 (fr) | Nouveaux dérivés de bétaines n-iminopyridinium, leur préparation et leur application en tant que médicaments | |
| US4153710A (en) | N-(4-[2-(pyrazole-1-carbonamide)-ethyl]-benzenesulphonyl)-urea | |
| FR2495155A1 (fr) | Nouveaux 8-aminoalkyl-4-alkylisopsoralenes, leur procede de preparation et composition pharmaceutique les contenant | |
| JPS6160837B2 (OSRAM) | ||
| DE3123520A1 (de) | Gesaettigte aminocyclitderivate, ihre herstellung undsie enthaltende arzneimittel | |
| BE1001251A4 (fr) | Composition pharmaceutique comprenant un complexe de zinc organique et procede pour preparer le produit actif. | |
| DE3204630C2 (OSRAM) | ||
| JPS6031831B2 (ja) | ７−置換−８−アミノメチル−イソフラボン誘導体の製造方法 | |
| DE10135027A1 (de) | Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen | |
| CZ278281B6 (en) | ENOL ETHER OF 1,1-DIOXIDE OF 6-CHLORO-4-HYDROXY-2-METHYL-N- (2-PYRIDYL-2H-THIENO(2,3-c)-1,2-THIAZINECARBOXYLIC ACID AMIDE, PROCESS OF ITS PREPARATION AND ITS USE | |
| DE2039426A1 (de) | Indenylessigsaeure und Verfahren zu deren Herstellung | |
| EP0168309B1 (fr) | Nouveaux dérivés de l'isoxazoloquinoléinone, procédé et intermédiaires de préparation, application à titre de médicaments, et compositions les renfermant | |
| JPS5924975B2 (ja) | スルフアミル安息香酸類の製法 | |
| EP0022213A1 (de) | Benzothiazol-2(3H)-one-Derivate enthaltende Arzneimittel | |
| AT383806B (de) | Verfahren zur herstellung neuer verbindungen von furo-(3,4-c)-pyridinderivaten und von deren salzen |